Table 2 Incidence and maximum toxicity observed during CapIri-RT treatment (n=36 patients)

From: A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer

 

Grade 1

Grade 2

Grade 3

Grade 4

Haematologic

 Leucocytopenia

12

7

7

2

 Thrombocytopenia

2

 Anaemia

23

9

Gastrointestinal

 Nausea/vomiting

9

10

2

 Mucositis/stomatitis

2

 Diarrhoea

13

15

4

 Proctitis

11

4

 Abdomial cramping

6

4

Laboratory

 Hyperbilirubinaemie

2

1

 ALAT/ASAT elevation

3

3

1

 Creatinine elevation

3

Skin

 Hand-foot skin reaction

3

 Alopecia

5

 Radiation dermatits

12

7

Other

 Fatigue

11

6

1

 Cholinergic syndrome

2

  1. CTC, common toxicity criteria; NCI, National Cancer Institute.
  2. Adverse events are graded according to CTC of the NCI version 2.0.